Both Sildenafil (Revatio) and Tadalafil (Adcirca) effectively treat pulmonary arterial hypertension (PAH), but differ in administration and potential side effects. Choose the medication based on individual patient needs and response.
Dosage and Administration
Sildenafil (Revatio) is typically administered three times daily, while Tadalafil (Adcirca) is taken once daily. This difference significantly impacts patient adherence. The once-daily dosing of Tadalafil might improve compliance for some patients. However, individual titration is necessary to optimize therapy for each patient.
Side Effects Profile
Common side effects include headache, flushing, and dyspepsia. However, the frequency and severity of these effects can vary between individuals and medications. For example, Tadalafil might be associated with a higher incidence of back pain compared to Sildenafil.
Comparative Efficacy
Clinical trials show comparable efficacy for both drugs in improving exercise capacity and hemodynamics in PAH patients. However, head-to-head comparisons are limited. The best choice depends on individual patient characteristics and physician preference.
Patient Considerations
Factors like other medications the patient is taking, existing health conditions, and personal preferences should inform the choice. Regular monitoring of blood pressure, heart rate, and oxygen saturation is essential during treatment with either medication.
Summary Table
| Dosage Frequency | Three times daily | Once daily |
| Most Common Side Effects | Headache, flushing, dyspepsia | Headache, flushing, dyspepsia, back pain |
| Efficacy | Proven effective in improving PAH symptoms | Proven effective in improving PAH symptoms |
Drug Interactions
Both drugs can interact with nitrates and certain other medications. Thorough assessment of a patient’s medication history is critical before prescribing either Sildenafil or Tadalafil.
